Pharmafile Logo

The Clinical Trial Company

The Clinical Trial Company (TCTC) targets medium size clinical trials and novel products which lack a classical road map to the market.
Large CROs prioritise studies from the big pharma companies, for good business reasons. However, this approach sometimes disadvantages their SME clients who are equally keen to complete their clinical trials quickly. TCTC are experts in advanced therapies, such as cell and gene therapies, as well as orphan drug and biologics.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

Havas Life London

We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by strategically aligning promotion, medical education and PR across the product…

View Profile

Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make a positive contribution to patient care. Real world experience of…

View Profile

Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual stories and interactive experiences that connect with people.

View Profile

Uniphar

Uniphar Group is a trusted global partner to pharmaceutical, medtech, and supply chain and retail companies, working to improve patient access to medicines around the world.

View Profile

Company Details

Mere View Barn, Park Lane, Pickmere, Knutsford, WA16 0LG, UK
+44 1565 733 772

 Latest Content from PMHub 

Embracing the demands of the empowered ‘consumer-savvy’ patient by Ann Generlich

Our access to information, which is now constantly at our fingertips and the explosion of new technologies has shifted the buying power to increasingly ‘consumer-savvy’ patients. These are patients who choose...

The Art of Agile Marketing

The industry knows that it needs become more responsive to its stakeholders. An agile approach – which quickly improves results through a process of rapid market feedback and response –...

Could ketamine be the next big thing in depression?

Account Executive Will Frostick discusses the established treatment model for depression and its limitations, as well as a new entrant poised to revolutionise the field – ketamine.

Attracting doctors to low-demand specialties: A role for industry?

 One of the major problems that healthcare systems around the world face is a paucity of medically qualified staff entering particular specialties and subspecialties. This can be due to a...

Men vs Women in emerging markets

Our latest interactive infographic compares male vs female health characteristics in the BRIC emerging marketS

South Korea: The next global player?

In this paper, we will explore some of the key trends and outlooks for South Korea in more detail, including what lies behind its presence at the extremes of two...

20 questions: Round 4

As it's our 20th year anniversary, we invited our employees to play our version of 20 questions - this month "What’s been the funniest thing to happen to you whilst you’ve...

Will gene therapies finally be commercially viable to pharma?

Our latest Free Thinking white paper explores the science behind the idea of gene therapy and takes a look at some of the core challenges medical researchers have faced when...

Wargaming in HCV

The challenge:Our client had a product ready for launch in the HCV landscape. A number of new competitor products were expected to alter the market dynamics. Given the stage of...

Living with Lupus: Breaking the Silence

Published in eyeforpharma July 2017 by Mariel Metcalfe